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Recent findings link increased expression of the structurally complex ‘b’ pathway gangliosides GD1b, GT1b, GQ1b (CbG) to a
favourable clinical and biological behaviour in human neuroblastoma (NB). Seeking a model to probe these observations, we
evaluated four human NB cell lines. Very low CbG content (4–10%) in three of the four cell lines (LAN-5, LAN-1, SMS-KCNR)
reflected the ganglioside pattern observed in the most aggressive NB tumours. Pharmacological alterations of complex ganglioside
synthesis in vitro by a 5–7 day exposure to 5–10mM retinoic acid, which is employed in maintenance therapy of disseminated NB,
included markedly increased (i) relative expression of CbG (6.672.0-fold increase, P¼0.037), (ii) relative expression of the
analogous ‘a’ pathway gangliosides, termed CaG (6.471.4-fold increase in GM1a and GD1a; P¼0.010), and (iii) total cellular
ganglioside content (2.0–6.3-fold), which in turn amplified the accumulation of structurally complex gangliosides. Substantial increases
(2.7–2.9-fold) in the activity of GD1b/GM1a synthase (b-1,3-galactosyltransferase), which initiates the synthesis of CbG and CaG,
accompanied the all-trans retinoic acid (ATRA)-induced ganglioside changes. Thus, increased CbG synthesis in NB cell lines is
attributable to a specific effect of ATRA, namely induction of GD1b/GM1a synthase activity. Since the shift towards higher expression
of CbG and CaG during retinoic acid-induced cellular differentiation reflects a ganglioside pattern found in clinically less-aggressive
tumours, our studies suggest that complex gangliosides may play a role in the biological and clinical behaviour of NB.
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Increasing evidence has implicated gangliosides, a specific class of cell
surface glycosphingolipids, in the biological and clinical behaviour of
many types of tumours including human neuroblastoma (NB).
Gangliosides are overexpressed and actively shed by tumour cells
(Wu et al, 1986; Valentino et al, 1990; Li and Ladisch, 1991) and have
a number of biological properties that could conceivably alter
tumour–host interactions to influence the survival of the malignant
cells that carry these molecules (Hakomori, 1996). Our previous
studies have linked specific ganglioside changes in human NB
tumours to differences in the clinical and biological behaviour of this
tumour (Kaucic et al, 2001; Hettmer et al, 2003), and raise the
possibility that pharmacologically induced modulation of NB gang-
lioside content could have important consequences for outcome.
Gangliosides consist of a sialic acid-containing carbohydrate portion
and a lipid portion (ceramide) embedded in the outer leaflet of the cell
membrane. They are synthesised via two prominent pathways,
d e s i g n a t e d‘ a ’( G M 2 ,G M 1 a ,G D 1 a )a n d‘ b ’( G D 3 ,G D 2 ,G D 1 bG T 1 b ,
GQ1b), from a common precursor (GM3) derived from lactosylcer-
amide (Figure 1). Each ganglioside is structurally more complex than
its precursor molecule, and the stepwise addition of monosaccharide
or sialic acid residues by specific membrane-bound glycosyltrans-
ferases in the Golgi apparatus is catalysed by the same glycosyl-
transferases in both pathways (van Echten and Sandhoff, 1993).
Our previous studies have characterised ganglioside expression
in human NB, a paediatric malignancy of neural crest origin (Wu
et al, 1986; Valentino et al, 1990; Kaucic et al, 2001; Hettmer et al,
2003). We have linked alterations in the expression of complex ‘b’
pathway gangliosides (CbG) downstream of GD1b/GM1a synthase
(GD1b, GT1b and GQ1b) to differences in the biological phenotype
and clinical behaviour that can be used to predict patient outcome
in NB (Hettmer et al, 2003). Further, recent experimental evidence
suggests that GD1b, GT1b and GQ1b can modulate a number of
biological processes that are believed to counteract malignant
transformation and progression, including tumour cell prolifera-
tion, host immune function and signal transduction mechanisms
(Hynds et al, 1995; Fukumoto et al, 2000; Kanda et al, 2001; Kanda
and Watanabe, 2001). We hypothesise that high CbG content may
contribute to reduced tumour aggressiveness, and that alteration
of CbG expression might be a potential therapeutic target in NB.
One pharmacological agent that is well known to alter cellular
ganglioside metabolism and successfully used in the oral main-
tenance therapy of disseminated NB is retinoic acid (Matthay et al,
1999). Previous in vitro studies have shown that morphological
signs of neuronal differentiation in response to retinoic acid are
accompanied by an increase in total ganglioside content and a
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srelative increase in the expression of certain complex gangliosides
of both the ‘a’ and ‘b’ pathway in NB cells (Li and Ladisch, 1992;
Rebhan et al, 1994), as well as in normal and transformed
embryonal cells (Levine and Flynn, 1986; Rizzo et al, 1995; Liour
et al, 2000). On the basis of these findings, we have undertaken a
comprehensive analysis of retinoic acid-induced changes in
ganglioside expression and metabolism in human NB cell lines.
Here, we demonstrate that low CbG levels in some NB cell lines
are analogous to the ganglioside pattern observed in clinically and
biologically unfavourable NB tumours, providing an in vitro model
to study pharmacological agents that might alter the metabolism of
complex ganglioside subspecies. We further demonstrate that
treatment with retinoic acid markedly enhances the activity of
GD1b/GM1a synthase, resulting in increased expression of the
complex gangliosides downstream of this enzyme, namely GD1b
and GT1b (CbG), and GM1a and GD1a (CaG). Our results thus
identify a specific effect of retinoic acid on the expression and
biosynthesis of complex gangliosides in NB cells.
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Figure 1 Schematic representation of the major pathways of ganglioside biosynthesis. (A) The monosialoganglioside GM3, derived from lactosylceramide,
is the common precursor for both ‘a’ and ‘b’ pathway gangliosides. Each ganglioside species consists of a ceramide backbone (CER), and a carbohydrate chain
(glc¼glucose, gal¼galactose, GalNAc¼N-acetylgalactosamine) containing one or more sialic acid (SA) residues. ‘a’ and ‘b’ pathway gangliosides
downstream of GD1b/GM1a synthase were designated complex ‘a’ (CaG) and complex ‘b’ (CbG) gangliosides, respectively. (B) Parallel steps in both
pathways are catalysed by the same glycosyltransferases of the Golgi apparatus (Li and Ladisch, 1997): (1), GD3 synthase (a-2,8-sialyltransferase): (2), GM2/
GD2 synthase (b-1,4-N-acetylgalactosaminyltransferase); (3), GD1b/GM1a synthase (b-1,3-galactosyltransferase); (4), GT1b/GD1a synthase (a-2,3-
sialyltransferase); (5), GQ1b/GT1a synthase (a-2,8-sialyltransferase). For each enzyme, accession numbers according to the NCBI protein bank are included.
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sMATERIALS AND METHODS
Cell culture
Human NB cell lines LAN-1, LAN-5, SMS-KCN and SMS-KCNR
were derived from three children with disseminated NB and have
been previously described. SMS-KCN and SMS-KCNR were
established from the same patient, from the primary tumour and
bone marrow at relapse, respectively (Kohl et al, 1983; Reynolds
et al, 1986; Rettig et al, 1987).
LAN-1 and LAN-5 were maintained in Waymouth’s MB 752/1
medium (GIBCO, Grand Island, NY, USA), and SMS-KCN and
SMS-KCNR in RPMI 1640 medium (GIBCO, Grand Island, NY,
USA). The medium was supplemented with 2mML -glutamine and
10% heat-inactivated foetal calf serum (GIBCO, Grand Island, NY,
USA), respectively. Cells were grown in adherent monolayer
cultures using 75-cm
2 and 175-cm
2 cell culture flasks (Becton
Dickinson, Franklin Lakes, NJ, USA) at 371C in a 5% CO2
atmosphere in a humidified incubator.
Retinoic acid (all-trans or 13-cis; Sigma Chemical Co., St Louis,
MO, USA) was dissolved in ethanol to a concentration of 10
 2 M
and kept as stock solution for up to 4 weeks at  701C, protected
from light. For each experiment, stock solutions were diluted with
the growth medium to a final concentration of 5 or 10mM retinoic
acid. These concentrations are equivalent to the serum levels
effective in the oral maintenance therapy of disseminated NB with
13-cis retinoic acid (13-cis RA) (7.275.3mM) (Reynolds and
Lemons, 2001). The final concentration of ethanol in the culture
medium was p0.2% (vv
 1).
Cells were seeded at 7 10
4 cells cm
 2. After 24h, the medium
was replaced with a medium containing retinoic acid. Culture
medium was replaced with fresh medium containing retinoic acid
every other day. Untreated control cells were grown with and
without ethanol. Cells were harvested after 5–7 days of exposure to
retinoic acid, followed by ganglioside purification or extraction of
crude membrane extracts, as described below. Viable cells were
counted using trypan blue dye exclusion and the cellular protein
content was estimated by the Bio-Rad DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA), using a bovine serum albumin
standard.
Ganglioside purification and quantification
Methods for extraction and purification of gangliosides were
previously described (Ladisch and Gillard, 1985). Briefly, total lipid
extracts of cell pellets were obtained by extracting the lyophilised
cell pellets twice with chloroform/methanol (1:1vv
 1)a t4 1C with
stirring. Gangliosides were isolated by partitioning the dried total
lipid extract in diisopropyl ether/1-butanol/17mM aquaeous NaCl
(6:4:5vv
 1). Gangliosides, in the lower aqueous phase, were
further purified by Sephadex G-50 gel filtration.
High-performance thin layer chromatography (HPTLC) analysis
of gangliosides (Ledeen and Yu, 1982) was performed using
10 10- or 10 20cm precoated silica gel HPTLC plates (Merck,
Darmstadt, Germany). The plates were developed in chloroform/
methanol/0.25% CaCl2 H2O (60:40:9 by volume), and the gang-
liosides were stained with resorcinol. Absolute cellular ganglioside
content was determined by HPTLC densitometry using known
concentrations of human brain gangliosides (HBG) as the
standard. Radioactive products were visualised by exposure of
HPTLC plates to an X-ray film (BioMax, Kodak).
Individual gangliosides were identified using a human brain
ganglioside standard or
14C-labelled rat brain gangliosides. The
area under the peak generated by each ganglioside band was
integrated after the plates/films were scanned (Microtek Scan-
Maker 5), and the relative percentage was calculated. To categorise
individual ganglioside species, we used a previously established
classification scheme based on biosynthetic pathways (Hettmer
et al, 2003). Structurally complex molecules downstream of GD1b/
GM1a synthase (b-1,3-galactosyltransferase) were designated
complex ‘a’ gangliosides (CaG: GM1a, GD1a and GT1a) and
complex ‘b’ gangliosides (CbG: GD1b, GT1b and GQ1b), respec-
tively.
Glycosyltransferase assays
The enzymatic activities of a-2,8-sialyltransferase (GD3 synthase),
b-1,4-N-acetylgalactosaminyltransferase (GD2 synthase) and b-1,3-
glactosyltransferase (GD1b synthase) were measured in membrane
extracts from retinoic acid-treated and control cells by incorpora-
tion of radiolabelled sugars into ganglioside precursors (Kemp and
Stoolmiller, 1976; Pohlentz et al, 2000).
Preparation of crude membrane extracts Crude membrane
fractions, used as the source of enzymes, were prepared by
suspending cell pellets in five volumes of cold 0.25 M sucrose
containing 0.01 M 2-mercaptoethanol. Cells were disrupted using
eight cycles of freezing in liquid nitrogen and thawing in a water
bath at 371C. After centrifugation at 2000g for 10min to remove
cellular debris, the supernatant fractions were centrifuged at
10000g for 10min and then sedimented at 100000g for 1h (Kemp
and Stoolmiller, 1976). The sedimentable fractions were resus-
pended in unbuffered sucrose (0.25 M) and the amount of
membrane protein was determined using the Bio-Rad DC Protein
Assay (Bio-Rad Laboratories, Hercules, CA, USA).
Processing of glycosyltransferse assays Triton X-100 (50mg, Sigma
Chemical Co., St Louis, MO, USA), ganglioside precursors and
radiolabelled sugar donors in chloroform/methanol (1:1vv
 1)
were transferred to 1ml conical glass tubes and the solvent was
evaporated under a stream of nitrogen. The corresponding buffer
mixture and unlabelled sugar donor were added, the mixture was
shaken vigorously, and each sample was sonicated for 30s.
Reaction mixtures were completed by addition of 50–150mg
membrane protein to a final reactive volume of 50ml and shaken
gently. After incubation at 371C for 1h, reactions were terminated
by addition of 1ml chloroform/methanol (2:1vv
 1) (Kemp and
Stoolmiller, 1976; Pohlentz et al, 2000).
a-2,8-sialyltransferase (GD3 synthase) activity was determined
using 30nmol GM3 (Sigma Chemical Co., St Louis, MO, USA),
0.01mCi
14C-labelled CMP sialic acid ([sialic-4,5,6,7,8,9-
14C],
150mCimmol
 1), 10nmol ‘cold’ CMP sialic acid, 2.5mmol of
MES buffer (pH 5.9), 2.5mmol of KCl, 0.1mmol of MnCl2 and
0.3mmol of MgCl2.
To assess b-1,4-N-acetylgalactosaminyltransferase (GD2
synthase) activity, 30nmol GD3 (Matreya Inc., Pleasant Gap, PA,
USA), 0.01mCi
3H]-labelled UDP N-acetyl-D-galactosamine ([ga-
lactosamine-1-
3H(N)], 5Cimmol
 1), 14nmol ‘cold’ N-acetyl-D-
galactosamine, 2.5mmol MES (pH 6.5) and 1.5mmol MnCl2 were
used.
For evaluation of b-1,3-glactosyltransferase (GD1b synthase)
activity, the reaction mixture contained 10nmol GD2 (Sigma
Chemical Co., St Louis, MO, USA), 0.01mCi
14C-labelled UDP
galactose ([galactose–
14C](U), 250mCimmol
 1), 20nmol ‘cold’
galactose, 2.5mmol MES (pH 6.5) and 2.1mmol MnCl2.
For each glycosyltransferase assay, buffer mixtures containing
MES (Calbiochem, San Diego, CA, USA), KCl, MnCl2 and MgCl2
(Sigma Chemical Co., St Louis, MO, USA) were freshly prepared.
Radiolabelled and ‘cold’ sugar donors were obtained from Perkin–
Elmer Life Sciences Inc. (Boston, MA, USA) and Calbiochem (San
Diego, CA, USA), respectively. All enzyme assays were performed
in duplicates with the appropriate blank.
Separation of lipid-soluble reaction products Lipid-soluble com-
pounds in the reaction mixture were isolated by passing them
through columns of Sephadex G25 Superfine (1 3–5cm in
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s150mm Pasteur pipettes, stuffed with glass wool). Sephadex G25
Superfine (Sigma Chemical Co., St Louis, MO, USA) was
suspended in water (5g per 60ml), stored overnight at 41C and
shaken vigorously. Before pouring the columns, the gel was
brought to room temperature and washed twice with the original
volume of methanol (X30min each time). One-third of the
supernatant was decanted, the mixture was shaken vigorously to
obtain a homogenous solution and the Pasteur pipettes were filled
to the top. After the solvent had drained, the gel was overlayed
with 1.5ml methanol and equilibrated with chloroform/methanol/
water (120:60:9vv
 1). The stopped samples were applied to the
columns, the sample tubes washed with 1ml chloroform/metha-
nol/water (120:60:9vv
 1) and elution of the products was
completed by adding 2ml of the latter (Pohlentz et al, 2000).
Determination of glycosyltransferase activities and product identi-
fication To measure the rate of incorporation of radiolabelled
sugars, the column effluents were transferred in part (40%) to glass
scintillation vials, evaporated to dryness under a stream of
nitrogen, and dissolved in 10ml Betafluor (National Diagnostics,
Mannville, NJ, USA). Radioactivity (measured as d.p.m.) was
determined in a Beckman LS6500 liquid scintillation counter.
Quench correction was accomplished using the AutoDPM
program. Enzyme activity (pmolh
 1mg protein
 1) was calculated
from the ratio of the products and the radioactivity of the total
sample. The remainder of the sample was used to confirm the
identity and the purity of the product by TLC autoradiography.
Statistical analysis
The relative expression of individual gangliosides and ganglioside
subsets (CbG and CaG) in each of the four cell lines studied were
expressed as the mean7s.e.m. for three to five separate experi-
ments. For the three cell lines that were responsive to retinoic acid,
the relative ganglioside content was similarly reported as the
mean7s.e.m. and, alternatively, the per cent of the expression of
parallel control cells for two separate experiments per cell line.
Data from six separate experiments involving three different cell
lines were normalised by relating results in each experimental
group to their respective controls by expressing the experimental
(exp) levels as a per cent of the control (ctrl) levels (exp/ctrl 100).
Control values of zero were set to 1 before the computation. To test
the hypothesis that experimental values differed from controls, we
employed a t-test to examine whether the experimental values
differed from 100%. The same method was used to compare
glycosyltransferase activities among retinoic acid-treated and
control cells in retinoic acid-responsive cell lines (LAN-1, LAN-5,
SMS-KCNR). Results were considered statistically significant if the
P-value was less than 0.050.
To examine whether experimental values differed from controls
in studies of 13-cis RA, mean treatment values were compared to
control values (no treatment with 13-cis RA) using a t-test.
RESULTS
Ganglioside expression in human NB cell lines
The impetus for this study were our findings (Hettmer et al, 2003)
and those of others (Schengrund et al, 1985; Sung et al, 1995; Yates
et al, 1999), suggesting that differences in tumour tissue CbG
(GD1b, GT1b and GQ1b) expression are linked to the clinical and
biological behaviour of NB and other tumours. In order to obtain
an in vitro model that permits a more dynamic view of NB
ganglioside biosynthesis, we analysed ganglioside expression in
four well-described NB cell lines, LAN-1, LAN-5, SMS-KCNR and
SMS-KCN.
To analyse ganglioside expression, we grew NB cells to 80–90%
confluence, then extracted total cellular gangliosides and separated
them by HPTLC (Figure 2). Gangliosides were measured (i) as
absolute cellular ganglioside content (nmol lipid-bound sialic acid
(LBSA)10
8 cells
 1) and (ii) as relative percentages of individual
gangliosides out of total cellular gangliosides. Absolute cellular
ganglioside content differed widely among the NB cell lines studied
(69nmol LBSA10
8 cells
 1 for SMS-KCN, 57nmol LBSA10
8 cells
 1
for LAN-5, 30nmol LBSA10
8 cells
 1 for LAN-1 and 15nmol
LBSA10
8 cells
 1 for SMS-KCNR). Nevertheless, there were clear
similarities in the relative ganglioside content of the four cell lines
(Table 1). The most prominent components were the ‘b’ pathway
disialoganglioside GD2 (26–60%) and the ‘a’ pathway mono-
sialoganglioside GM2 (22–35%). Complex ‘b’ pathway ganglio-
sides represented only minor components (p10%) in three of the
four NB cell lines studied (10% in LAN-5, 4% in LAN-1 and 8% in
SMS-KCNR), and were composed of the disialylated molecule
GD1b (2%) and the trisialylated ganglioside GT1b (2–8%). The
fourth cell line, SMS-KCN, contained 21% CbG (2% GD1b and 19%
GT1b). There were no detectable amounts of the most complex
molecule, GQ1b, in any of the cell lines studied.
The prominent position of GD2 as a major ganglioside
component in the NB cell lines studied (44% in LAN-5, 36% in
LAN-1, 60% in SMS-KCNR and 26% in SMS-KCN) mirrors the
GM1a
GD1b
GQ1b
GM2
GD1a
GD2
GT1b
HBG LAN-5 LAN-1 KCNR KCN
Figure 2 Ganglioside expression in four human NB cell lines (LAN-5,
LAN-1, SMS-KCNR, SMS-KCN). Human brain gangliosides (HBG) were
employed as a standard. GD2, GD1a and GT1b are doublets in tumour
samples. The lower GD1a band and the upper GD2 band overlap.
Table 1 Ganglioside expression in neuroblastoma cell lines
Ganglioside expression (% of total cellular gangliosides)
a
LAN-5 LAN-1 SMS-KCNR SMS-KCN
GM3 0702 710 701 70
‘a’ pathway
GM2 35783 5 712 22743 4 75
GM1a 2711 701 702 71
GD1a 2700 703 701 7 75
CaG 4711 704 701 8 75
‘b’ pathway
GD3 8732 2 747 721 70
GD2 44753 6 786 0 762 6 74
GD1b 2712 712 712 71
GT1b 8722 717 731 9 73
GQ1b 0700 700 700 70
CbG 10734 728 732 1 74
aValues represent means7s.e.m. of three independent experiments, except for
LAN-5 which consisted of five independent experiments.
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subiquitously high expression of GD2 that characterizes NB
tumours (Wu et al, 1986). Importantly, the low CbG expression
observed in each of the cell lines is also analogous to the CbG levels
found in clinically and biologically unfavourable NB tumours
(Hettmer et al, 2003). We therefore used these four NB cell lines as
an in vitro model to determine whether retinoic acid, as a
pharmacological agent, might alter the expression and biosynth-
esis of CbG.
Retinoic-acid induced changes in CbG expression in NB
cell lines
Retinoids are a class of vitamin A derivatives that differ in their
isomeric conformations, and include all-trans retinoic acid
(ATRA), 9-cis retinoic acid and 13-cis RA. Owing to its superior
pharmacokinetics (higher and more sustained plasma levels), 13-
cis RA is the isomer that is primarily used clinically. However, 13-
cis RA isomerises in vivo to both ATRA and 9-cis retinoic acid,
which are believed to be the active compounds in vivo in
nonocular tissue (Lovat et al, 1994). Since retinoic acid treatment
has been associated with changes in the ganglioside complement of
various cell types (Li and Ladisch, 1992; Rebhan et al, 1994; Liour
et al, 2000), and the oral maintenance therapy of disseminated NB
with 13-cis RA results in improved event-free survival (Matthay
et al, 1999), we sought to specifically explore the effect of retinoic
acid on CbG expression. We, therefore, first treated NB cells in
vitro with 10mM ATRA, then evaluated ATRA-induced changes in
the composition of individual gangliosides and in total cellular
ganglioside content in LAN-1, LAN-5, SMS-KCNR and SMS-KCN
cells (Table 2). Strikingly, ATRA induced a shift from synthesis of
simpler gangliosides towards more complex species within both
the ‘a’ and ‘b’ pathways in three of the four cell lines (LAN-1, LAN-
5 and SMS-KCNR). In these three cell lines, the redistribution
towards complex gangliosides included increased relative expres-
sion of GD1b and GT1b (‘b’ pathway) and GM1a and GD1a
(‘a’ pathway), compounded by a substantial increase in total
cellular ganglioside content, making the increase in the absolute
content of CbG and CaG even more striking (Table 2). In
LAN-5 cells for example, the ATRA-induced changes in cellular
ganglioside expression included a 3.7-fold increase in CbG
content (from 6 to 22%), a 2.2-fold increase in CaG content (from
4 to 9%) and a two-fold increase in absolute ganglioside content
(from 57 to 112nmol10
8 cells
 1). SMS-KCN, the cell line with
the highest baseline level of CbG, was the only cell line of the
four which was not responsive to ATRA treatment; specifically,
the change in complex ganglioside content was minimal (23 vs
23% CbG and 24 vs 18% CaG in controls compared to ATRA-
treated cells), as was the change in total cellular ganglioside
Table 2 Effect of ATRA on neuroblastoma cell ganglioside expression
Relative ganglioside expression (% of total cellular gangliosides)
a Absolute ganglioside expression (nmol10
 8 cells
 1)
GD1b+GT1b (CbG) GD2 GD3 GD1a+GM1a (CaG) GM2 GM3 Total CbG
b CaG
b
LAN-1
Ctrl 3722 9 711 8 711 704 8 723 71 30 0.9 0.3
ATRA 13732 9 716 758 724 4 751 70 70 9.1 5.6
LAN-5
Ctrl 6744 8 735 724 723 8 760 70 57 3.4 2.3
ATRA 22753 2 733 719 733 5 740 70 112 24.6 10.1
SMS-KCNR
Ctrl 10756 4 798 744 711 6 710 70 15 1.5 0.6
ATRA 40732 7 721 713 0 715 740 70 94 37.6 28.2
SMS-KCN
Ctrl 23782 1 721 702 4 711 31771 70 69 15.9 16.6
ATRA 23741 1 716 751 8 764 3 766 74 50 11.5 9.0
aValues represent means7standard errors of two independent experiments.
bCalculated from the absolute total ganglioside content and the mean relative content of CaG or
CbG. ATRA¼all-trans retinoic acid; Ctrl¼control; CbG¼complex ‘b’ pathway gangliosides; CaG¼complex ‘a’ pathway gangliosides.
Table 3 Relative changes in neuroblastoma cell ganglioside expression in ATRA-responsive cell lines
Ganglioside expression in ATRA-treated cells (% of control)
Exp
a GD1b+GT1b (CbG) GD2 GD3 GD1a+GM1a (CaG) GM2 GM3
LAN-1 a 250 96 6 1000 104 33
b 1500 104 53 600 80 50
LAN-5 a 300 57 67 220 97 100
b 850 76 57 300 91 100
SMS-KCNR a 740 38 25 967 50 100
b 307 45 0 750 7 100
Mean7s.e.m.
b 6587202 69711 35712 6407137 72715 80713
P-value
c 0.037 0.040 0.002 0.010 0.117 0.180
aFor each cell line, two separate experiments (a and b) were analysed.
bMean7s.e.m. of normalised values for all three cell lines (two experiments per cell line; six experiments
total). Bold values are statistically significant (Po0.050).
ct-tests. ATRA¼all-trans retinoic acid; CbG¼complex ‘b’ pathway gangliosides; CaG¼complex ‘a’ pathway gangliosides.
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8 cells
 1). When normalised data
from the three responsive cell lines were analysed together
(Table 3), ATRA treatment clearly resulted in significant
increases in the cellular content of CbG (6587202% of control,
P¼0.037) and CaG (6407137% of control, P¼0.010), and,
concomitantly, significant decreases in the cellular content of
GD2 (69711% of control; P¼0.040) and GD3 (35712%
of control; P¼0.002).
To illustrate these changes, Figure 3 summarises the ATRA-
induced changes in cell morphology and ganglioside expression
of the NB cell line SMS-KCNR. The morphological changes
in response to ATRA, including rounding up of the cell
body, extension of long processes with the appearance of neurites
and cell aggregation into tight clusters (Figure 3A), are consist-
ent with previous studies evaluating the differentiating effects of
ATRA on NB cells (Li and Ladisch, 1992; Melino et al, 1997).
Qualitative changes in the composition of cell-surface gangliosides
accompanied morphological signs of differentiation in response
to ATRA. The most prominent ganglioside components in
untreated SMS-KCNR cells were the ‘b’ pathway ganglioside GD2
and the ‘a’ pathway ganglioside GM2. Treatment with
ATRA increased the proportions of the CbG (GD1b and GT1b),
as well as the CaG (GD1a and GM1a), such that these
two subgroups predominated relative to other ganglioside
species (Figure 3B). In view of the increase in total cellular
ganglioside content (Table 2), this relative change resulted
in significant absolute changes in the membrane expression of
complex ganglioside molecules. Thus, the mean four-fold
increase in relative CbG expression translated into a 25-fold
increase in absolute cellular CbG expression in SMS-KCNR cells,
indicating a striking accumulation of these biologically
active molecules.
Since 13-cis RA is currently the only retinoid compound in
clinical use to treat NB (Reynolds and Lemons, 2001), we also
exposed one NB cell line, LAN-1, to 13-cis RA at two different
concentrations (5mM,1 0mM). We observed that 13-cis RA caused a
concentration-related increase in the expression of structurally
complex gangliosides in LAN-1 cells (Figure 4). As with ATRA-
treated cells, the increase in CbG expression was paralleled by a
concurrent increase in CaG, suggesting a specific effect of retinoids
on the activity of GD1b/GM1a synthase (b-1,3-galactosyltransfer-
ase), which initiates the synthesis of both CbG and CaG, from GD2
and GM2, respectively.
Ctrl 10 µM ATRA
GM1a
GD1b
GQ1b
GT1b
GD2
GD1a
GM2
HBG Ctrl Ctrl* ATRA
A
B
Figure 3 Effect of all-trans retinoic acid (ATRA) on cell morphology (A)
and cellular ganglioside expression (B) in the human NB cell line SMS-
KCNR. Cells were plated at 7 10
4 cells and treated with ATRA 10mM on
days 1–7. Photomicrograph ( 100) was obtained on day 6. Cells were
harvested on day 7, and gangliosides were purified and separated by
HPTLC (Ctrl, medium alone; Ctrl*, medium containing 0.1% ethanol;
ATRA, medium containing 10mM ATRA). GD2, GD1a and GT1b are
doublets in tumour samples. The lower GD1a band and the upper GD2
band overlap.
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Figure 4 Effect of 13-cis retinoic acid (13-cis RA) on CbG (GD1b,
GT1b; black bars) and CaG (GM1a, GD1a; grey bars) expression in LAN-1
human NB cells. Bars represent means7s.e.m. Ganglioside subsets are
expressed as a percentage of total cellular gangliosides. Experimental and
controls values were compared using a t-test (*Po0.050).
Table 4 Effect of ATRA on neuroblastoma (NB) cell glycosyltransferase
activities
Enzyme activity (pmolh
 1 mg protein)
a
GD1b synthase GD2 synthase GD3 synthase
LAN-5
Ctrl 215 1416 572
ATRA 572 1384 669
SMS-KCNR
Ctrl 172 518 364
ATRA 497 927 511
SMS-KCN
Ctrl 186 1143 333
ATRA 283 769 405
aActivities of GD1b synthase, GD2 synthase and GD3 synthase in NB cells treated
with 10mM all-trans retinoic acid (ATRA) are compared to untreated cells (Ctrl).
Enzyme activities were determined by incorporation of radiolabelled sugars into
ganglioside precursors. Values represent means from duplicate samples of one to two
experiments. ATRA¼all-trans retinoic acid; Ctrl¼control; CbG¼complex ‘b’
pathway gangliosides; CaG¼complex ‘a’ pathway gangliosides.
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sEffect of retinoic acid on the activity of ganglioside
glycosyltransferases in human NB cells in vitro
To delineate the metabolic basis for the ATRA-induced shift
towards expression of complex gangliosides, we determined the
effect of ATRA treatment on the activity of three key enzymes in
the synthesis of these molecules. Precursor molecules enter ‘b’
pathway ganglioside biosynthesis through conversion of GM3 into
GD3 by GD3 synthase (a-2,8-sialyltransferase). GD2/GM2 synthase
(b-1,4-N-acetylgalactosaminyltransferase) and GD1b/GM1a
synthase (b-1,3-glactosyltransferase) catalyse the two subsequent
enzymatic reactions resulting in the synthesis of the most complex
gangliosides in each pathway (van Echten and Sandhoff, 1993)
(Figure 1). We measured the activities of GD3 synthase, GD2
synthase and GD1b synthase in crude membrane extracts from
LAN-5, SMS-KCNR, SMS-KCN, using excess GM3, GD3 and GD2
as exogenously added ganglioside precursors.
When the retinoic acid-responsive LAN-5 or SMS-KCNR
cells were exposed to 10mM ATRA for 6–7 days (Table 4), we
observed a marked increase (2.7–2.9-fold, Po0.050) in
GD1b synthase activity. This was accompanied by a lesser
(0–1.8-fold, P¼0.198) increase in GD2 synthase activity,
and only small changes in GD3 synthase activity (1.2–1.4,
P¼0.161). Thus, in both LAN-5 and SMS-KCNR cells, increased
expression of complex gangliosides downstream of GD1b
sythase was associated with a significant (over two-fold) increase
in GD1b synthase activity. In contrast, in SMS-KCN cells, the cell
line that was unresponsive to ATRA treatment, GD1b synthase
activity was only slightly increased (1.5-fold) in ATRA-treated vs
control cells.
Figure 5 illustrates the autoradiographic visualisation of enzyme
products resulting from ATRA-induced changes in ganglioside
metabolism in SMS-KCNR cells, confirming the major increase in
GD1b synthase activity (Figure 5A), a comparatively minor
increase in GD2 synthase activity (Figure 5B) and almost no
change in GD3 synthase activity (Figure 5C). It is interesting to
note that in the case of the ATRA-treated cell samples, the parallel
blank (which does not contain exogenously added ganglioside
precursors) also shows the synthesis of GD1b and GM1a from the
trace amounts of endogenous gangliosides present in the cell pellet
(Figure 5A), further confirming the substantial increase in the
activity of GD1b/GM1a synthase following treatment with ATRA.
Taken together, our data demonstrate that the increase in GD1b
synthase activity is specifically associated with increased expres-
sion of complex ganglioside species, induced by ATRA in NB cells
in vitro, and provides strong evidence that elevated CbG and CaG
expression can be accounted for by a specific effect of ATRA on
this enzyme.
DISCUSSION
Treatment with retinoic acid is shown here to induce a dramatic
shift from synthesis of simpler gangliosides towards predominant
expression of structurally complex ‘a’ and ‘b’ pathway ganglioside
molecules downstream of GD1b/GM1a synthase in some NB cell
lines. The increase in total cellular ganglioside content combined
with the relative changes in the proportion of complex gangliosides
results in a significant increase in the absolute cellular content of
these molecules. The findings are consistent with the previous
observations of a dramatic increase in membrane expression and
shedding of total cellular gangliosides and enhancement in GD1a
and GT1b content in LAN-5 NB cells treated with retinoic acid (Li
and Ladisch, 1992).
Among the four cell lines employed in this study, the NB cell line
SMS-KCN appears to be biologically distinct. Three differences are
evident. First, SMS-KCN cells consist of two morphologically
distinct cell populations, one neuroblastic (N-type) and the second
substrate-adherent (S-type) with epithelial or fibroblast-like
morphology (Rettig et al, 1987), while LAN-1, LAN-5 and SMS-
KCNR exhibit a uniform phenotype with small, round, neuro-
blastic cells that have short neuritic processes. Second, constitutive
CbG content in SMS-KCN was higher (1.8- to 5.2-fold) than in the
other cell lines studied. Third, treatment with retinoic acid did not
induce the alterations in cellular ganglioside biosynthesis observed
in the other cell lines. These differences in ganglioside metabolism
GD1b synthase
GD2 synthase
GD3 synthase
RBG  blank 1 2 blank 1 2
Ctrl ATRA
GD3
GD2
GD1b
GM1a
A
B
C
Figure 5 Effect of all-trans retinoic acid (ATRA) on the activities of
GD1b synthase, GD2 synthase and GD3 synthase in the human NB cell line
SMS-KCNR. HPTLC autoradiograms demonstrate reaction products from
assays measuring activities of GD1b synthase (A), GD2 synthase (B) and
GD3 synthase (C). Enzyme assays were performed in duplicate (1,2) with
an appropriate ‘blank’ (Ctrl, medium alone; ATRA, 10mM).
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are accounted for by constitutive differences between N-type and
S-type cells.
One possible explanation for the retinoic acid-induced changes
in ganglioside composition in LAN-1, LAN-5 and SMS-KCNR cells
is an increased rate of synthesis of certain gangliosides. A previous
study in embryonal carcinoma cells demonstrated enhanced
activities of various ganglioside glycosyltransferases at different
stages of retinoic acid-induced neuronal differentiation, and a
parallel increase in mRNA expression, suggesting that retinoic acid
activated the transcription of these glycosyltransferases or
stabilised their expression (Osanai et al, 1997; Liour et al, 2000).
Our data support that the retinoic acid-induced increase in the
expression of complex gangliosides both within the ‘a’ and the ‘b’
pathway is attributable to an induction of GD1b/GM1a synthase
(b-1,3-glactosyltransferase) activity. The retinoic acid-induced
alterations in the ganglioside complement of NB cells seem to
reflect, therefore, a specific effect on ganglioside anabolism,
although, theoretically, alterations in ganglioside catabolism or
shedding are also possible contributing factors. Increased
expression of complex gangliosides is a well-described feature of
normal embryonic neurogenesis and accelerated axonogenesis
(Svennerholm et al, 1989; Hirschberg et al, 1996). Similar
ganglioside changes to those we describe here have been reported
in retinoic acid-treated Xenopus embryo cells, murine embryonal
carcinoma cells and SHSY-5Y NB cells during neuronal maturation
(Rebhan et al, 1994; Rizzo et al, 1995; Liour et al, 2000).
Thus, predominant expression of complex gangliosides can be
considered a biochemical marker of increasing neuronal differ-
entiation. Further, the retinoic acid-induced changes in the
ganglioside, complement of NB cell lines, are analogous to
reported differences in CbG content among prognostically distinct
categories of NB tumours (Schengrund et al, 1985; Schengrund and
Shochat, 1988; Hettmer et al, 2003). Specifically, we previously
found that among 74 human NB tumours, high (X35%) CbG
expression (a) characterised nonprogressive vs progressive
tumours (median 41 vs 18% of total gangliosides), and (b) was
strongly predictive of a favourable outcome, even when other
prognostic factors were considered (Hettmer et al, 2003). Related
studies, associating low CbG levels in astrocytoma and medullo-
blastoma with higher histological grades and lower survival
(Sung et al, 1995; Yates et al, 1999), further support the value of
CbG in discriminating between different categories of malignant
disease. In this context, the retinoic acid-induced increase in
CbG expression in NB cells represents a transition into a
ganglioside pattern which is associated with (i) neuronal
differentiation in normal cells and (ii) clinically less-aggressive
NB tumours, suggesting that CbGs may play a role in the biological
behaviour of NB.
Tumour gangliosides of aberrant structure are generally believed
to favour tumour progression (Hakomori, 1996), and a substantial
body of previous experimental evidence associates the shedding
of tumour cell surface gangliosides with increased tumori-
genicity (Ladisch et al, 1987). The relationship between the
concentration of shed GD2 in the plasma of NB-bearing patients
and reduced long-term survival (Valentino et al, 1990) is
consistent with this concept. There is also experimental evidence
that suggests that the biological effects of tumour-derived gang-
liosides differ greatly depending on their carbohydrate and
ceramide structures (Floutsis et al, 1989; Ladisch et al, 1994).
Here we hypothesise that the significantly higher CbG levels in
clinically favourable NB tumours (Hettmer et al, 2003) may lead
to reduced NB tumour aggressiveness. Substantial experimental
evidence corroborates the concept that the prognostic value of
CbG reflects their functional involvement in the cellular processes
that define the malignant behaviour of NB. Malignant transforma-
tion of murine epidermal cells in response to tumour-promoting
phorbol esters is accompanied by a decrease in GT1b synthesis
(Srinivas and Colburn, 1982). Proliferation of and IL-8 production
by human metastatic melanoma cells is inhibited by GD1b,
GT1b and GQ1b (Kanda et al, 2001). Platelet-derived growth
factor (PDGF)-mediated cell growth and PDGF receptor activation
in NB and glioma cells are inhibited by complex ganglioside
species (Hynds et al, 1995). These gangliosides also modulate
immunoglobulin synthesis in peripheral blood mononuclear
cells (Kanda and Tamaki, 1998, 1999a,b) and cause a shift
from Th-2 to Th-1 cytokine production in PHA-stimulated
T cells (Kanda et al, 2001). Finally, increased expression of
GD1b and GT1b in rat pheochromocytoma cells transfected with
GD3 synthase occurs in parallel with trk-A dimerisation (Fuku-
moto et al, 2000), which in turn is associated with improved
prognosis in NB (Nakagawara et al, 1993). Taking these findings
together, we hypothesise that CbG may impede tumour progres-
sion, either by acting directly on the tumour cell or by increasing
the host resistance.
Similarly, increased tumour CbG expression might contribute
to the success of retinoic acid in the maintenance therapy of
disseminated NB. The beneficial role of retinoic acid is generally
attributed to a reversal of the malignant state through differentia-
tion of the tumour cells into more mature ganglion-like cells
(Matthay et al, 1999; Reynolds and Lemons, 2001). Substantial
experimental evidence suggests that complex gangliosides are
biologically relevant molecules during cellular differentiation
and development. First, outgrowth of cellular extensions, one
aspect of neuronal differentiation, can be induced by treating
NB cells in vitro with exogenous gangliosides, and the CbG
species GT1b and GQ1b have been repeatedly described as the
two most potent ganglioside molecules with differentiating
properties (Tsuji et al, 1983; Leskawa and Hogan, 1985). Secondly,
increased expression of GD1b and GT1b in murine NB cells
transfected with GD3 synthase occurs in parallel with morpho-
logical signs of increased cellular differentiation (Kojima et al,
1994). Thirdly, absence of all gangliosides downstream of GM2/
GD2 synthase (CbGþGD2 and CaGþGM2) in genetically
altered mice with a disrupted gene for that enzyme is associated
with decreased myelination and axon degeneration in the
central and peripheral nervous system (Sheikh et al, 1999),
although brain development and gross behaviour is normal
(Takamiya et al, 1996). Finally, although retinoic acid-induced
neurite outgrowth is unaffected by abrogation of cellular ganglio-
side synthesis in LAN-5 cells grown in a serum-supplemented
environment (Li and Ladisch, 1997), reduction of cellular gang-
lioside synthesis is associated with decreased NGF-induced
outgrowth of neuritic processes in a NB cell line grown in
serum-free medium, and is reversible by exogenous addition of
gangliosides (Rosner, 1998).
Previous findings and our demonstration of induction of
CbG (and CaG) synthesis by retinoic acid underscore the
potential role of complex gangliosides in cellular differentiation
and other cellular functions important to reversion of the
malignant phenotype. Consequently, the specific role of complex
gangliosides compared to structurally simpler molecules in
influencing cellular differentiation and other cellular functions in
NB and other neuroectodermal tumours will be important to
delineate.
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